These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 16203650

  • 21. Effects of drospirenone/estrogen combinations on bone metabolism.
    Christiansen C.
    Climacteric; 2005 Oct; 8 Suppl 3():35-41. PubMed ID: 16203654
    [Abstract] [Full Text] [Related]

  • 22. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.
    Boschitsch E, Skarabis H, Wuttke W, Heithecker R.
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600
    [Abstract] [Full Text] [Related]

  • 23. The role of antiandrogens in hormone replacement therapy.
    Schneider HP.
    Climacteric; 2000 Dec; 3 Suppl 2():21-7. PubMed ID: 11379383
    [Abstract] [Full Text] [Related]

  • 24. Yasmin--a new oral contraceptive, a new progestogen: the reasons why.
    Mansour D.
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():9-16. PubMed ID: 11246601
    [Abstract] [Full Text] [Related]

  • 25. Drospirenone, a progestogen with antimineralocorticoid properties: a short review.
    Oelkers W.
    Mol Cell Endocrinol; 2004 Mar 31; 217(1-2):255-61. PubMed ID: 15134826
    [Abstract] [Full Text] [Related]

  • 26. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception.
    Africander D, Verhoog N, Hapgood JP.
    Steroids; 2011 Jun 31; 76(7):636-52. PubMed ID: 21414337
    [Abstract] [Full Text] [Related]

  • 27. Yasmin: the reason why.
    Thorneycroft IH.
    Eur J Contracept Reprod Health Care; 2002 Dec 31; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
    [Abstract] [Full Text] [Related]

  • 28. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits.
    Sitruk-Ware R.
    Menopause; 2002 Dec 31; 9(1):6-15. PubMed ID: 11791081
    [Abstract] [Full Text] [Related]

  • 29. Effects of drospirenone on cardiovascular markers in human aortic endothelial cells.
    Seeger H, Wallwiener D, Mueck AO.
    Climacteric; 2009 Feb 31; 12(1):80-7. PubMed ID: 18979300
    [Abstract] [Full Text] [Related]

  • 30. Conception and pharmacodynamic profile of drospirenone.
    Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A.
    Steroids; 2003 Nov 31; 68(10-13):891-905. PubMed ID: 14667981
    [Abstract] [Full Text] [Related]

  • 31. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen.
    Krattenmacher R.
    Contraception; 2000 Jul 31; 62(1):29-38. PubMed ID: 11024226
    [Abstract] [Full Text] [Related]

  • 32. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms.
    Apter D, Borsos A, Baumgärtner W, Melis GB, Vexiau-Robert D, Colligs-Hakert A, Palmer M, Kelly S.
    Eur J Contracept Reprod Health Care; 2003 Mar 31; 8(1):37-51. PubMed ID: 12725674
    [Abstract] [Full Text] [Related]

  • 33. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure.
    Oelkers WK.
    Steroids; 1996 Apr 31; 61(4):166-71. PubMed ID: 8732994
    [Abstract] [Full Text] [Related]

  • 34. Hormone therapy and the cardiovascular system: the critical role of progestins.
    Sitruk-Ware RL.
    Climacteric; 2003 Oct 31; 6 Suppl 3():21-8. PubMed ID: 15018245
    [Abstract] [Full Text] [Related]

  • 35. Pharmacological profile of progestins.
    Sitruk-Ware R.
    Maturitas; 2008 Oct 31; 61(1-2):151-7. PubMed ID: 19434887
    [Abstract] [Full Text] [Related]

  • 36. Progestins and breast cancer.
    Pasqualini JR.
    Gynecol Endocrinol; 2007 Oct 31; 23 Suppl 1():32-41. PubMed ID: 17943537
    [Abstract] [Full Text] [Related]

  • 37. YAZ and the novel progestin drospirenone.
    Mishell DR.
    J Reprod Med; 2008 Sep 31; 53(9 Suppl):721-8. PubMed ID: 18980044
    [Abstract] [Full Text] [Related]

  • 38. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models.
    Muhn P, Krattenmacher R, Beier S, Elger W, Schillinger E.
    Contraception; 1995 Feb 31; 51(2):99-110. PubMed ID: 7750297
    [Abstract] [Full Text] [Related]

  • 39. [Contraception with pure, synthetic progestogens of the norpregnane group, a new approach for the future?].
    Rozenbaum H.
    Contracept Fertil Sex (Paris); 1986 Jun 31; 14(6):577-81. PubMed ID: 12341096
    [Abstract] [Full Text] [Related]

  • 40. Pharmacokinetics and pharmacodynamics of drospirenone-estradiol combination hormone therapy product coadministered with hydrochlorothiazide in hypertensive postmenopausal women.
    Karara AH, Hanes V, Alonso A, Ni P, Poola N, Silang R, Blode H, Preston RA.
    J Clin Pharmacol; 2007 Oct 31; 47(10):1292-302. PubMed ID: 17906162
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.